(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2006 (11.05.2006)

PCT

(10) International Publication Number
WO 2006/048751 A1

(51) International Patent Classification:
C07D 401/06 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4439 (2006.01) *A61P 31/00* (2006.01)

(21) International Application Number:
PCT/IB2005/003312

(22) International Filing Date: 21 October 2005 (21.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/624,665 2 November 2004 (02.11.2004) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HART, Ryan, Marshal** [US/US]; Pfizer Global Research and Development, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **KANIA, Robert, Steven** [US/US]; Pfizer Global Research and Development, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **OUELLETTE, Michael** [US/US]; Pfizer Global Research and Development, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **WU, Zhen, Ping** [CN/US]; Pfizer Global Research and Development, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **YE, Qiang** [CN/US]; Pfizer Global Research and Development, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US). **ZOOK, Scott, Edward** [US/US]; Pfizer Global Research and Development, Agouron/Pfizer La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **FULLER, Grover, F.** et al.; c/o DROUIN, Stéphane, Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYMORPHIC FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE

(57) Abstract: The present invention relates to novel polymorphic forms of 6-[2 (methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity.

WO 2006/048751 A1